Melox: Uses, Dosage & Side Effects

What Is Melox and What Is It Used For?

Melox contains the active substance meloxicam, a member of the oxicam class of non-steroidal anti-inflammatory drugs (NSAIDs). Meloxicam is classified as a preferential cyclooxygenase-2 (COX-2) inhibitor, meaning that at therapeutic doses it preferentially inhibits the COX-2 enzyme over the COX-1 enzyme. This pharmacological distinction is clinically important because the COX-2 isoform is primarily responsible for the production of prostaglandins involved in inflammation and pain, while the COX-1 isoform plays a protective role in maintaining gastrointestinal mucosal integrity, renal blood flow, and platelet aggregation. By preferentially targeting COX-2, meloxicam provides effective anti-inflammatory and analgesic activity while potentially causing fewer gastrointestinal adverse effects compared to traditional non-selective NSAIDs.

The mechanism of action of meloxicam centers on the inhibition of prostaglandin synthesis. Prostaglandins, particularly prostaglandin E2 (PGE2) and prostacyclin (PGI2), are lipid mediators derived from arachidonic acid through the catalytic activity of cyclooxygenase enzymes. In inflammatory conditions, the inducible COX-2 enzyme is upregulated in response to inflammatory stimuli such as cytokines (interleukin-1, tumor necrosis factor-alpha), growth factors, and bacterial lipopolysaccharides. The resulting increase in prostaglandin synthesis leads to the cardinal signs of inflammation: vasodilation (redness and warmth), increased vascular permeability (swelling), sensitization of pain receptors (pain), and fever. By inhibiting COX-2 and reducing prostaglandin synthesis at sites of inflammation, meloxicam effectively reduces pain, swelling, stiffness, and functional impairment associated with musculoskeletal conditions.

Melox is specifically formulated as a solution for injection (10 mg/ml) to provide a parenteral route of administration when oral meloxicam is not suitable. The intramuscular route offers several clinical advantages in the acute setting. After intramuscular injection, meloxicam reaches peak plasma concentration (Cmax) within approximately 1 to 1.5 hours, which is significantly faster than the 5 to 6 hours typically required after oral administration. This rapid absorption translates to a quicker onset of analgesic and anti-inflammatory effects, making the injectable formulation particularly useful for patients experiencing acute flare-ups of pain who require prompt relief. The bioavailability after intramuscular injection is essentially 100%, compared to approximately 89% for the oral form.

The clinical indications for Melox injection include the short-term treatment of acute exacerbations of the following musculoskeletal conditions:

• Osteoarthritis (OA): The most common form of arthritis, affecting millions of people worldwide. OA is a degenerative joint disease characterized by the breakdown of articular cartilage, subchondral bone changes, osteophyte formation, and synovial inflammation. Patients with OA may experience acute flare-ups of pain and stiffness, particularly in weight-bearing joints such as the knees and hips. Melox injection can provide rapid relief during these acute episodes.
• Rheumatoid arthritis (RA): A chronic autoimmune inflammatory disease that primarily affects the joints, causing synovitis, cartilage destruction, and bone erosion. RA is characterized by periods of exacerbation (flares) and remission. During acute flares, patients may experience severe joint pain, swelling, and morning stiffness lasting more than 30 minutes. Melox injection can be used to rapidly manage the pain and inflammation of acute RA flares while disease-modifying therapies take effect.
• Ankylosing spondylitis (AS): A chronic inflammatory disease primarily affecting the axial skeleton (spine and sacroiliac joints), leading to back pain, stiffness, and potentially spinal fusion. Acute exacerbations of AS can be severely debilitating, and the injectable form of meloxicam can provide more rapid symptom relief compared to oral therapy when patients are unable to tolerate oral medications or when faster onset is clinically desirable.

Once the acute phase has been managed and the patient can tolerate oral medication, treatment should be transitioned from Melox injection to oral meloxicam. The recommended duration of injectable treatment is limited to a maximum of one to two days. Meloxicam is available in oral forms (tablets and oral suspension) in strengths of 7.5 mg and 15 mg for continued maintenance therapy. The long elimination half-life of meloxicam (approximately 20 hours) supports once-daily dosing for both the injectable and oral formulations.

What Should You Know Before Taking Melox?

Contraindications

Melox must not be used in patients with the following conditions, as the risks clearly outweigh any potential therapeutic benefits:

• Hypersensitivity to meloxicam or any excipient: Known allergy to meloxicam or to any of the other ingredients in the formulation is an absolute contraindication. Allergic reactions to NSAIDs can range from mild skin reactions to severe anaphylaxis.
• Cross-reactivity with aspirin and other NSAIDs: Patients who have experienced asthma, nasal polyps, angioedema, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs must not use Melox. This syndrome, known as aspirin-exacerbated respiratory disease (AERD) or Samter's triad, occurs because COX inhibition diverts arachidonic acid metabolism toward the lipoxygenase pathway, leading to increased production of cysteinyl leukotrienes that trigger bronchoconstriction and inflammation. These cross-reactive hypersensitivity reactions can be severe and potentially life-threatening.
• Active gastrointestinal bleeding or perforation: Melox is contraindicated in patients with active peptic ulcer disease, gastrointestinal bleeding, or a history of NSAID-related gastrointestinal perforation. NSAIDs inhibit prostaglandin-mediated cytoprotection of the gastric mucosa, increasing the risk of mucosal injury. Active bleeding represents a particularly dangerous scenario where further COX inhibition could worsen hemorrhage.
• Severe hepatic insufficiency: In patients with severe liver disease, the metabolism of meloxicam is significantly impaired, leading to accumulation of the drug and increased risk of adverse effects. Additionally, prostaglandins play an important role in maintaining hepatic blood flow, and their inhibition could worsen hepatic function.
• Severe renal insufficiency without dialysis: Prostaglandins (particularly PGE2 and PGI2) play a crucial role in maintaining renal blood flow and glomerular filtration rate, especially in patients with reduced effective arterial blood volume. In severe renal insufficiency, inhibition of prostaglandin synthesis by NSAIDs can precipitate acute renal failure.
• Uncontrolled heart failure: NSAIDs can cause fluid retention and edema through their effects on renal sodium and water handling. In patients with uncontrolled heart failure, this fluid retention can worsen the condition and increase the risk of cardiovascular events.
• Third trimester of pregnancy: NSAIDs are contraindicated in the third trimester because they can cause premature closure of the ductus arteriosus in the fetus, impair fetal renal function leading to oligohydramnios, and inhibit uterine contractions potentially prolonging labor. The risk of these complications increases significantly after 30 weeks of gestation.

Warnings and Precautions

Before receiving Melox, your healthcare provider should be informed about the following conditions and risk factors:

• History of gastrointestinal disease: Patients with a prior history of peptic ulcer disease, gastrointestinal bleeding, or inflammatory bowel disease (Crohn's disease or ulcerative colitis) are at increased risk of gastrointestinal complications. Concomitant use of gastroprotective agents such as proton pump inhibitors (PPIs) should be considered in high-risk patients.
• Cardiovascular disease: Patients with established cardiovascular disease, hypertension, congestive heart failure, or significant cardiovascular risk factors (diabetes, hyperlipidemia, smoking) should use Melox with caution. The risk of cardiovascular events may be dose-dependent and time-dependent. Clinical trials and meta-analyses have shown that NSAID use is associated with a small but statistically significant increase in the risk of atherothrombotic events.
• Renal impairment: Melox should be used with caution in patients with mild to moderate renal impairment. Renal function should be monitored, and adequate hydration should be maintained. The dose may need to be adjusted, and the duration of treatment should be as short as possible. Patients receiving diuretics, ACE inhibitors, or ARBs alongside Melox are at particular risk of acute renal injury.
• Hepatic impairment: In patients with mild to moderate liver disease, Melox should be used with caution and liver function tests should be monitored. If abnormal liver function tests persist or worsen, treatment should be discontinued.
• Elderly patients: Older adults are at increased risk of all NSAID-related adverse effects, including gastrointestinal bleeding, cardiovascular events, and renal impairment. The lowest effective dose should be used for the shortest possible duration, and patients should be monitored closely for signs of complications.
• Bleeding disorders: Meloxicam, like other NSAIDs, may impair platelet function and prolong bleeding time. Patients with coagulation disorders or those taking anticoagulants should be monitored carefully.

Pregnancy and Breastfeeding

Melox is contraindicated during the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus, fetal renal dysfunction, and inhibition of labor. During the first and second trimesters, Melox should only be used if the potential benefit justifies the potential risk to the fetus. Epidemiological data suggest that NSAID use during early pregnancy may be associated with an increased risk of miscarriage and certain congenital malformations, although the absolute risk increase is small. Women of childbearing potential should be advised that NSAIDs, including meloxicam, may impair fertility by affecting ovulation; this effect is reversible upon discontinuation of treatment.

Meloxicam is excreted in the breast milk of lactating rats, although human data are limited. NSAIDs are generally present in low concentrations in human breast milk. As a precaution, Melox should be avoided during breastfeeding. If treatment is considered essential, the decision to continue or discontinue breastfeeding should be made in consultation with the healthcare provider, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

Children and Adolescents

The injectable form of meloxicam (Melox) is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established in this population for the intramuscular route. Oral meloxicam formulations are approved for use in children over 2 years of age in some countries for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis) at an appropriate weight-based dose. Healthcare providers should use age-appropriate formulations and dosing guidelines for pediatric patients.

Driving and Operating Machinery

Meloxicam may occasionally cause dizziness, drowsiness, or visual disturbances. If you experience any of these effects after receiving a Melox injection, you should not drive or operate heavy machinery until you are sure that you are unaffected. Patients should be advised of these potential effects and counseled to exercise caution when performing activities requiring alertness.

How Does Melox Interact with Other Drugs?

Drug interactions with meloxicam can be broadly categorized into pharmacodynamic interactions (where the combined physiological effects of two drugs lead to an increased risk of adverse events) and pharmacokinetic interactions (where one drug affects the absorption, distribution, metabolism, or excretion of another). As an NSAID that inhibits prostaglandin synthesis and has effects on platelet function, renal hemodynamics, and gastrointestinal mucosal integrity, meloxicam can interact with numerous other drug classes. Understanding these interactions is essential for safe prescribing and administration.

Meloxicam is extensively metabolized in the liver, primarily by the cytochrome P450 enzymes CYP2C9 and, to a lesser extent, CYP3A4. While meloxicam is not a potent inhibitor or inducer of CYP enzymes, drugs that significantly affect CYP2C9 activity can alter meloxicam's metabolism. Additionally, meloxicam is highly protein-bound (more than 99% to plasma albumin), meaning that displacement interactions with other highly protein-bound drugs are theoretically possible, although they are rarely clinically significant because the free drug is rapidly redistributed and eliminated.

Major Interactions

The most clinically significant interactions with Melox involve anticoagulants, other NSAIDs, lithium, and methotrexate. The combination of meloxicam with anticoagulants such as warfarin is particularly concerning because meloxicam impairs platelet function through COX-1 inhibition (at higher doses or in some individuals) and can damage the gastrointestinal mucosa, creating sites prone to bleeding. Case reports and pharmacoepidemiological studies have documented an increased risk of serious gastrointestinal hemorrhage when NSAIDs and anticoagulants are used concurrently. If co-administration is deemed necessary, the INR (international normalized ratio) should be monitored closely, particularly during the initiation and discontinuation of Melox.

Concurrent use of two or more NSAIDs (including low-dose aspirin for cardiovascular prophylaxis) increases the risk of gastrointestinal ulceration and bleeding without providing additional therapeutic benefit. Patients taking low-dose aspirin for cardiovascular protection should be aware that meloxicam may reduce the antiplatelet effect of aspirin through competitive inhibition at the COX-1 binding site. If both medications are needed, careful timing of administration (taking aspirin at least 2 hours before the NSAID) may help preserve aspirin's cardioprotective effect, though this approach has not been definitively validated in clinical trials.

The interaction between meloxicam and lithium is clinically important because NSAIDs reduce renal prostaglandin synthesis, leading to decreased renal blood flow and reduced lithium clearance. This can result in elevated serum lithium levels and lithium toxicity, which can manifest as tremor, confusion, renal impairment, and in severe cases, cardiac arrhythmias and seizures. Serum lithium levels should be monitored when initiating, adjusting, or discontinuing meloxicam in patients receiving lithium therapy.

Minor Interactions

Several additional interactions are worth noting, although they are generally of lesser clinical significance. Cholestyramine, a bile acid sequestrant, can bind meloxicam in the gastrointestinal tract and accelerate its elimination through interruption of enterohepatic recycling, potentially reducing its therapeutic effect. Oral antidiabetic medications (sulfonylureas) may have their hypoglycemic effect enhanced when used with NSAIDs, though this interaction is generally mild and clinically insignificant with meloxicam. Antacids, H2 receptor antagonists, and proton pump inhibitors do not significantly affect the absorption or pharmacokinetics of meloxicam.

It should be noted that meloxicam may reduce the efficacy of intrauterine devices (IUDs) for contraception, although this has been reported primarily with other NSAIDs and the clinical relevance specifically to meloxicam is uncertain. Women using IUDs should discuss this potential interaction with their healthcare provider.

What Is the Correct Dosage of Melox?

Melox injection is intended for short-term parenteral therapy when rapid onset of pain relief is required. The dosing strategy follows the fundamental NSAID prescribing principle of using the lowest effective dose for the shortest possible duration. This approach minimizes the risk of dose-dependent adverse effects, particularly gastrointestinal, cardiovascular, and renal complications. The following dosing recommendations are based on current clinical guidelines and regulatory approved product information.

Adults

The injection must be administered by a healthcare professional using aseptic technique. Melox should be injected deeply into the gluteal muscle (upper outer quadrant of the buttock) to ensure proper absorption and to minimize the risk of local tissue damage. The injection should never be administered intravenously, as this can cause severe adverse reactions. Subcutaneous or intradermal injection should also be avoided, as these routes may cause local irritation, sterile abscess formation, or tissue necrosis.

Children

Melox injection is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of intramuscular meloxicam have not been established in the pediatric population. For children over 2 years of age who require NSAID therapy, oral meloxicam formulations are available in some countries with appropriate weight-based dosing (typically 0.125 mg/kg once daily, up to a maximum of 7.5 mg). Pediatric patients should always be treated under the supervision of a healthcare provider experienced in managing musculoskeletal conditions in children.

Elderly

Elderly patients (65 years and older) are at significantly increased risk of NSAID-related adverse effects. Age-related changes in physiology, including reduced renal function, decreased hepatic blood flow, altered body composition, and increased susceptibility to gastrointestinal injury, all contribute to this elevated risk profile. In elderly patients, the recommended dose of Melox injection is 7.5 mg (0.75 ml) once daily, and this should not be exceeded. Treatment duration should be as short as clinically possible. Close monitoring for signs of gastrointestinal bleeding (dark stools, hematemesis), fluid retention, and changes in renal function is essential during and after treatment.

Missed Dose

Since Melox injection is administered by healthcare professionals in a clinical setting, missed doses are unlikely to occur. If a scheduled injection is inadvertently delayed, it should be administered as soon as possible, but the total daily dose should not exceed 15 mg (or 7.5 mg in high-risk populations). Do not administer two injections within a short interval to make up for a missed dose. If more than 24 hours have elapsed, resume the normal dosing schedule or transition to oral meloxicam as clinically appropriate.

Overdose

NSAID overdose with meloxicam may present with a range of symptoms including nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, lethargy, and in severe cases, hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, and cardiovascular collapse. Although meloxicam overdose is rarely fatal, serious complications can occur, particularly in elderly patients and those with pre-existing organ impairment.

There is no specific antidote for meloxicam overdose. Treatment is supportive and symptomatic. Activated charcoal may be beneficial if administered within one hour of oral ingestion of excessive doses. Administration of cholestyramine (4 grams three times daily) has been shown to accelerate the elimination of meloxicam by interrupting its enterohepatic circulation. In severe cases, intensive monitoring of vital signs, renal function, hepatic function, and fluid balance is required. Hemodialysis is not expected to be effective in removing meloxicam due to its extensive protein binding (>99%).

What Are the Side Effects of Melox?

Like all medications, Melox can cause side effects, although not everyone experiences them. The side effect profile of injectable meloxicam is consistent with that of the oral formulation and reflects the pharmacological effects of NSAID therapy in general. Side effects are categorized below by their approximate frequency of occurrence, as established through clinical trials and post-marketing surveillance data. Understanding the frequency and nature of potential side effects helps patients and healthcare providers make informed treatment decisions and facilitates early recognition of adverse reactions.

It is important to note that the injectable form of Melox is intended for short-term use only (1–2 days), which significantly limits the duration of exposure and reduces the overall risk of adverse effects. However, even short-term NSAID use carries some risk, particularly for serious gastrointestinal and cardiovascular events in susceptible individuals. Patients should be informed of the signs and symptoms that warrant immediate medical attention.

Gastrointestinal side effects are the most frequently reported adverse reactions associated with NSAID use. Meloxicam's preferential COX-2 selectivity provides a degree of gastrointestinal protection compared to non-selective NSAIDs, but the risk is not eliminated entirely. A landmark meta-analysis published in The Lancet (Coxib and Traditional NSAID Trialists' Collaboration, 2013) demonstrated that meloxicam is associated with a lower rate of upper gastrointestinal complications compared to non-selective NSAIDs such as diclofenac, naproxen, and ibuprofen, although the difference is less pronounced than with selective COX-2 inhibitors (coxibs) such as celecoxib.

Injection site reactions specific to the intramuscular formulation include pain at the injection site, which is the most common local adverse effect. Less frequently, induration (hardening), erythema (redness), and sterile abscess formation may occur. Proper injection technique (deep intramuscular injection into the gluteal muscle) minimizes the risk of these local reactions. Injection site reactions are generally mild and self-limiting, resolving within a few days without specific treatment.

How Should You Store Melox?

Proper storage of Melox injection is essential to maintain its chemical stability, sterility, and therapeutic efficacy. As a parenteral formulation intended for intramuscular injection, maintaining the integrity of the solution is critical for patient safety. The following storage conditions apply to both unopened and in-use containers.

Melox injection should be stored at a temperature not exceeding 25°C (77°F). The ampoules or vials should be kept in the original carton to protect from light exposure, as meloxicam solution may undergo photodegradation when exposed to direct sunlight or intense artificial light for prolonged periods. Do not freeze the solution, as freezing can alter the physicochemical properties of the formulation and may compromise the stability of the active ingredient or excipients.

The solution should be clear and free from visible particles before use. If the solution appears discolored, cloudy, or contains precipitate, it should not be used and should be disposed of according to local pharmaceutical waste disposal regulations. Once an ampoule is opened, the contents should be used immediately and any remaining solution should be discarded. Melox ampoules are intended for single use only and do not contain preservatives; therefore, opened ampoules must never be stored for later use due to the risk of microbial contamination.

Since Melox injection is almost exclusively administered in healthcare settings (hospitals, clinics, emergency departments), storage is typically managed by pharmacy departments or clinical staff who maintain appropriate temperature-controlled environments. Patients rarely need to store this medication at home. However, in exceptional circumstances where the medication is dispensed for home administration by a visiting healthcare professional, the patient should be instructed to keep the ampoules in their original packaging, at room temperature, away from children, and to return any unused medication to the pharmacy for safe disposal.

As with all medications, Melox should not be used after the expiry date stated on the packaging. The expiry date refers to the last day of that month. Expired medications should be returned to a pharmacy for proper disposal rather than being discarded in household waste or flushed down the drain, as pharmaceutical waste can contaminate water supplies and the environment.

What Does Melox Contain?

Melox solution for injection is a clear, yellow to yellow-green solution formulated for intramuscular administration. The formulation has been carefully designed to ensure that meloxicam, which has poor aqueous solubility in its un-ionized form, is maintained in a stable solution suitable for parenteral use. Understanding the composition of the formulation can be helpful for identifying potential allergenic excipients and for patients with specific sensitivities or dietary requirements.

Active Ingredient

The active ingredient in Melox is meloxicam, present at a concentration of 10 mg per milliliter. Meloxicam (chemical name: 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) is an enolic acid derivative belonging to the oxicam class of NSAIDs. It has a molecular weight of 351.4 g/mol and appears as a pale yellow powder in its pure form. Meloxicam is practically insoluble in water at neutral pH but is solubilized in the injection formulation through the use of alkaline pH conditions and appropriate excipients.

Excipients (Inactive Ingredients)

• Meglumine (N-methylglucamine): Serves as a counterion to form the water-soluble meloxicam meglumine salt, enabling the preparation of a clear aqueous solution at the required concentration. Meglumine also helps maintain an alkaline pH that keeps meloxicam in its ionized, soluble form.
• Poloxamer 188: A non-ionic surfactant (polyoxyethylene-polyoxypropylene block copolymer) that helps maintain the stability of the formulation and prevents precipitation of meloxicam upon dilution or temperature changes.
• Glycine: An amino acid used as a buffering agent to help maintain the pH of the solution within the optimal range for stability and tolerability after injection.
• Sodium chloride: Used to adjust the osmolality (tonicity) of the solution to approximate that of physiological fluids, minimizing pain and tissue damage upon intramuscular injection.
• Sodium hydroxide: Used during manufacturing to adjust the pH of the solution. The final pH of the solution is typically in the range of 8.0 to 9.0, which is necessary to maintain meloxicam in solution.
• Water for injections: The solvent vehicle, manufactured to meet pharmacopoeial standards for parenteral preparations (sterile, pyrogen-free, low in endotoxins).

Melox injection does not contain lactose, gluten, tartrazine, parabens, or sulfites. It is suitable for patients with lactose intolerance or celiac disease. The formulation does not contain any ingredients of animal origin. However, patients with known hypersensitivity to any of the listed excipients should not receive this medication. If you are unsure about potential allergies, consult with your healthcare provider or pharmacist before treatment.